Kunle Odunsi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4523591/publications.pdf

Version: 2024-02-01

130	10,194	53794	40979
papers	citations	45 h-index	93 g-index

134	134	134	18064
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	2.5	2
2	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
3	VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients. Cancer Immunology, Immunotherapy, 2022, 71, 2355-2369.	4.2	5
4	Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Science Translational Medicine, 2022, 14, eabg8402.	12.4	28
5	Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunology, Immunotherapy, 2022, 71, 2881-2898.	4.2	4
6	Tissue residency of memory CD8+ TÂcells matters in shaping immunogenicity of ovarian cancer. Cancer Cell, 2022, 40, 452-454.	16.8	2
7	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
8	Population-based targeted sequencing of 54 candidate genes identifiesPALB2as a susceptibility gene for high-grade serous ovarian cancer. Journal of Medical Genetics, 2021, 58, 305-313.	3.2	26
9	Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer. JAMA Oncology, 2021, 7, 78.	7.1	103
10	Circulating CD14 + HLAâ€ÐR lo/â˜' monocytic cells as a biomarker for epithelial ovarian cancer progression. American Journal of Reproductive Immunology, 2021, 85, e13343.	1.2	4
11	Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€•(December 4thâ€“5th,) Tj ETQq1 1 0.784314 rg	4.4	3
12	Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion. Journal of the National Cancer Institute, 2021, 113, 1036-1043.	6.3	50
13	RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization. Communications Biology, 2021, 4, 102.	4.4	28
14	IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation. Frontiers in Immunology, 2021, 12, 678999.	4.8	40
15	A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer. Cancer Immunology, Immunotherapy, 2021, 70, 3451-3460.	4.2	9
16	Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer. ELife, 2021, 10, .	6.0	15
17	Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer. Cancer Immunology Research, 2021, 9, 790-810.	3.4	29
18	Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. IScience, 2021, 24, 102757.	4.1	20

#	Article	IF	Citations
19	GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. Clinical Cancer Research, 2021, 27, 5536-5545.	7.0	15
20	Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass. Scientific Reports, 2021, 11, 18156.	3.3	11
21	Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation. Molecular Therapy - Oncolytics, 2021, 23, 38-50.	4.4	9
22	CXCR6 by increasing retention of memory CD8⁺ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. , 2021, 9, e003329.		25
23	RNA Splicing and Immune-Checkpoint Inhibition. New England Journal of Medicine, 2021, 385, 1807-1809.	27.0	3
24	The Great Debate at â€˜Immunotherapy Bridgeâ€™, Naples, December 5, 2019. , 2020, 8, e000921.		3
25	Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability. Cancers, 2020, 12, 764.	3.7	47
26	Transmission of X-linked Ovarian Cancer: Characterization and Implications. Diagnostics, 2020, 10, 90.	2.6	5
27	Sublethal Radiation Affects Antigen Processing and Presentation Genes to Enhance Immunogenicity of Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 2573.	4.1	9
28	Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils. Cancer Immunology Research, 2020, 8, 819-828.	3.4	25
29	Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. , 2019, 7, 189.		41
30	Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing. BMC Medical Informatics and Decision Making, 2019, 19, 14.	3.0	16
31	Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. , 2019, 7, 156.		65
32	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	5.5	54
33	Immune Checkpoint and Poly(ADPâ€“Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers. JAMA Oncology, 2019, 5, 1103.	7.1	2
34	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	2.8	6
35	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2019, 30, 537-547.	1.8	16
36	Epigenetic activation of POTE genes in ovarian cancer. Epigenetics, 2019, 14, 185-197.	2.7	24

#	Article	IF	Citations
37	A rare population of tumor antigen-specific CD4+CD8+ double-positive Î±Î² T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells. , 2019, 7, 7.		14
38	Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. British Journal of Cancer, 2019, 120, 207-217.	6.4	62
39	Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight, 2019, 4, .	5.0	93
40	Oncologist uptake of comprehensive genomic profile guided targeted therapy. Oncotarget, 2019, 10, 4616-4629.	1.8	13
41	Hereditary association between testicular cancer and familial ovarian cancer: A Familial Ovarian Cancer Registry study. Cancer Epidemiology, 2018, 53, 184-186.	1.9	7
42	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
43	Anthropometric characteristics and ovarian cancer risk and survival. Cancer Causes and Control, 2018, 29, 201-212.	1.8	4
44	Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses. Cancer Immunology Research, 2018, 6, 236-247.	3.4	61
45	Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. Journal of Allergy and Clinical Immunology, 2018, 141, 1028-1035.	2.9	172
46	NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clinical Cancer Research, 2018, 24, 1019-1029.	7.0	87
47	Sialic Acidâ€"Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments. Journal of Immunology, 2018, 201, 3750-3758.	0.8	77
48	Expression of the POTE gene family in human ovarian cancer. Scientific Reports, 2018, 8, 17136.	3.3	21
49	Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer. PLoS ONE, 2018, 13, e0206913.	2.5	9
50	Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery. JAMA Network Open, 2018, 1, e185452.	5.9	100
51	Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 1025-1039.	2.2	11
52	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
53	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
54	Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. Clinical Cancer Research, 2017, 23, 3802-3812.	7.0	43

#	Article	IF	Citations
55	Gene expression markers of Tumor Infiltrating Leukocytes. , 2017, 5, 18.		572
56	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecologic Oncology, 2017, 145, 420-425.	1.4	61
57	Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. Gynecologic Oncology, 2017, 146, 52-57.	1.4	12
58	Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2017, 146, 137-145.	1.4	4
59	Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecologic Oncology, 2017, 146, 491-497.	1.4	53
60	A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 5055-5065.	7.0	62
61	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
62	Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells. Nature Communications, 2017, 8, 14649.	12.8	128
63	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes and Control, 2017, 28, 469-486.	1.8	28
64	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, 2017, 117, 1063-1069.	6.4	16
65	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1470-1473.	2.5	10
66	The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. International Journal of Gynecological Cancer, 2017, 27, 11-16.	2.5	9
67	A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 147, 283-290.	1.4	37
68	Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. OncoImmunology, 2017, 6, e1249561.	4.6	252
69	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	2.5	3
70	Immunotherapy in ovarian cancer. Annals of Oncology, 2017, 28, viii1-viii7.	1.2	276
71	Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression. Advances in Experimental Medicine and Biology, 2017, 1036, 129-144.	1.6	62
72	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget, 2017, 8, 3197-3205.	1.8	53

#	Article	IF	Citations
73	Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget, 2017, 8, 50930-50940.	1.8	43
74	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
75	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
76	Evaluation of satisfaction with workâ€“life balance among U.S. Gynecologic Oncology fellows: A cross-sectional study. Gynecologic Oncology Reports, 2016, 16, 17-20.	0.6	8
77	HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecologic Oncology, 2016, 142, 158-162.	1.4	8
78	The CD47 â€œdon't eat me signalâ€•is highly expressed in human ovarian cancer. Gynecologic Oncology, 2016, 143, 393-397.	1.4	53
79	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
80	Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. Scientific Reports, 2016, 6, 21591.	3.3	18
81	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
82	Synuclein-Î³ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease. Journal of Ovarian Research, 2016, 9, 75.	3.0	13
83	DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer. Molecular Cancer Research, 2016, 14, 787-794.	3.4	38
84	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	6.4	39
85	Synergistic COX2 Induction by IFNÎ³ and TNFÎ± Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunology Research, 2016, 4, 303-311.	3.4	53
86	Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy. OncoImmunology, 2016, 5, e1116675.	4.6	9
87	Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature. Metabolomics, 2016, 12, 1.	3.0	57
88	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
89	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
90	PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget, 2016, 7, 45352-45369.	1.8	72

#	Article	IF	Citations
91	Vaccination with NY-ESO-1 in Combination with Decitabine for Patients with MDS. Blood, 2016, 128, 4326-4326.	1.4	1
92	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
93	Use of Common Analgesics Is Not Associated with Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1291-1294.	2.5	7
94	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
95	LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget, 2015, 6, 27359-27377.	1.8	242
96	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
97	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
98	Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nature Communications, 2015, 6, 7458.	12.8	383
99	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
100	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
101	TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. Gynecologic Oncology, 2015, 138, 159-164.	1.4	21
102	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
103	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
104	Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade. Cancer Immunology Research, 2015, 3, 1269-1278.	3.4	84
105	Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. Oncotarget, 2015, 6, 11310-11326.	1.8	45
106	Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. Oncotarget, 2015, 6, 18641-18652.	1.8	20
107	Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression. Oncotarget, 2015, 6, 27613-27627.	1.8	54
108	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25

#	Article	IF	Citations
109	Satisfaction with work-life balance among U.S. gynecologic oncologists, a cross-sectional study. American Journal of Clinical and Experimental Obstetrics and Gynecology, 2015, 2, 166-175.	0.5	1
110	Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism. PLoS ONE, 2014, 9, e84941.	2.5	279
111	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. British Journal of Cancer, 2014, 111, 2297-2307.	6.4	76
112	LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. Gynecologic Oncology, 2014, 132, 462-467.	1.4	47
113	Tumor-associated macrophages: Co-conspirators and orchestrators of immune suppression in endometrial adenocarcinoma. Gynecologic Oncology, 2014, 135, 173-175.	1.4	13
114	Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer. Cancer Immunology Research, 2014, 2, 37-49.	3.4	168
115	Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e104099.	2.5	65
116	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 caseâ€“control studies. Cancer Causes and Control, 2013, 24, 989-1004.	1.8	84
117	Adjuvant treatment for uterine leiomyosarcoma. European Journal of Gynaecological Oncology (discontinued), 2013, 34, 409-14.	0.2	2
118	Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro. PLoS ONE, 2012, 7, e51030.	2.5	41
119	Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5797-5802.	7.1	173
120	Conventional Dose Hypomethylating Agents Induce CG Antigen Genes In Vivo. Blood, 2011, 118, 2441-2441.	1.4	1
121	Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenaseâ€“Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer. Cancer Research, 2009, 69, 5498-5504.	0.9	140
122	REVIEW ARTICLE: Harnessing the Immune System for Ovarian Cancer Therapy. American Journal of Reproductive Immunology, 2008, 59, 62-74.	1.2	20
123	Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12837-12842.	7.1	239
124	Detection of epithelial ovarian cancer using1H-NMR-based metabonomics. International Journal of Cancer, 2005, 113, 782-788.	5.1	322
125	Intraepithelial CD8⁺tumor-infiltrating lymphocytes and a high CD8⁺/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18538-18543.	7.1	2,100
126	Primary primitive neuroectodermal tumor of the uterus: a report of two cases and review of the literature. Gynecologic Oncology, 2004, 92, 689-696.	1.4	27

#	Article	IF	Citations
127	Phase I trial of the anti-idiotypic monoclonal antibody (mAb) ACA-125 in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology, 2004, 22, 5018-5018.	1.6	2
128	Vaccine therapy for cancer: fact or fiction?. Surgical Technology International, 2004, 13, 39-47.	0.2	0
129	NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Research, 2003, 63, 6076-83.	0.9	191
130	Evaluation of Î²1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer. American Journal of Obstetrics and Gynecology, 2002, 187, 575-580.	1.3	13